Adriano Gravina

Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer

Ana Oaknin, Anna V. Tinker, Lucy Gilbert et al. · JAMA Oncology · 2020 · 346 citations · Full text

Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial

Lucia Del Mastro, Sabino De Placido, Paolo Bruzzi et al. · The Lancet · 2015 · 196 citations

Breast Oncology, Medicine, Dose-dense Chemotherapy +6

Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors

Thierry André, Dominique Berton, Giuseppe Curigliano et al. · JAMA Network Open · 2023 · 103 citations · Full text

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis et al. · The Lancet Oncology · 2018 · 86 citations · Full text

Endocrine Oncology, Breast Oncology, Medicine +7

Endocrine Effects of Adjuvant Letrozole Compared With Tamoxifen in Hormone-Responsive Postmenopausal Patients With Early Breast Cancer: The HOBOE Trial

Emanuela Rossi, Alessandro Morabito, Francesca Di Rella et al. · Journal of Clinical Oncology · 2009 · 80 citations

Tamoxifen Result, Hormonal Contraceptive, Breast Oncology +19